X

Aggrego On Site

Top Stories
More NSCLC Downstaging With Neoadjuvant Chemotherapy Plus ICI

Neoadjuvant chemotherapy plus nivolumab resulted in a higher frequency of disease downstaging and lower frequency of upstaging compared with other therapies among patients with...

Cancer Therapy Advisor
11/12/2020
OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential

Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted onco

11/17/2020
``

ASCO 2021: Updates in CRC

Final Results Support Pembrolizumab as Standard of Care in MSI-H/dMMR Metastatic Colorectal Cancer

Pembrolizumab significantly improved PFS, but not OS, when compared with chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer...

Cancer Therapy Advisor
06/14/2021
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

Guardant Health presents new data at the 2021 ASCO Annual Meeting showing that its LUNAR-2 blood test is a highly sensitive test that can detect CRC in early-stage cancer patients.

06/04/2021
Capecitabine Maintenance Improves Progression-Free Survival in Metastatic Colorectal Cancer

Capecitabine maintenance improved PFS, but not OS, when compared with active monitoring in patients with metastatic colorectal cancer, according to data from the FOCUS4-N trial.

Cancer Therapy Advisor
06/10/2021
'Smart Bomb' Salvage in HER+ Metastatic CRC

The higher the HER2 expression, the more benefit patients get from the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive metastatic colorectal cancer in the salvage setting...

Medscape
06/07/2021
Pembrolizumab Shows Continued PFS Benefit in MSI-H/dMMR Metastatic Colorectal Cancer

Pembrolizumab demonstrates continued PFS benefit, with a trend for OS benefit, as first-line therapy for patients with MSI-H mCRC, compared with chemotherapy, in the final analysis of KEYNOTE-177.<

ASCO Daily News
06/09/2021
Chemotherapy/Local Excision Avoids Proctectomy in Rectal Cancer

Chemotherapy and local excision led to organ preservation in over half of early-stage rectal cancer patients in a small study, but follow-up was only a median of 15.4 months. Even so...

Medscape
06/08/2021

ASCO 2021: Updates in CAR-T

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

SHANGHAI, June 6, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated to Zhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001, a GPC3 CAR-T cell therapy for the treatment of relapsed/refractory hepatocellular carcinoma (HCC), at the 2021 annual meeting of American Society of Clinical Oncology. 

06/06/2021
Tecartus Demonstrates High Response Rate in Adults With R/R B-cell ALL Earning Priority Review Designation

Results of the primary analysis of Tecartus (brexucabtagene autoleucel) in adults with relapsed/refractory B-cell precursor ALL were simultaneously published in The Lancet and presented at

06/04/2021
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings

Legend Biotech announced today that new and updated results for ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-directed CAR-T therapy for R/R MM, will be featured at ASCO 2021 and a

06/01/2021
Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia

In a phase 1/2 trial, 8 of 11 patients with relapsed or refractory AML achieved a complete response with CAR T-cell therapy targeting C-type lectin-like molecule-1.

Cancer Therapy Advisor
06/06/2021
CAR-T Cell Therapy Shows Promise in Pretreated Patients With Multiple Myeloma

Ciltacabtagene autoleucel, a BCMA-targeting therapy, appears to show promising activity among patients with previously treated MM, per research presented at the 2021 ASCO Annual Meeting.

Hematology Advisor
06/06/2021

ASCO 2021: Updates in Lymphoma

Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma

Genentech today announced that new data on mosunetuzumab, glofitamab, and polatuzumab vedotin in NHL being presented at the 2021 ASCO Annual Meeting.

06/04/2021
Romidepsin and Lenalidomide Combination Effective as Initial Therapy for Peripheral T-Cell Lymphoma

The combination of romidepsin and lenalidomide is feasible and effective as initial therapy for patients with PTCL who are not candidates for cytotoxic CT, per research presented at ASCO 2021.

Cancer Therapy Advisor
06/04/2021
Penpulimab Shows Promise for Relapsed/Refractory Classic Hodgkin Lymphoma

Penpulimab led to an ORR of 89.4% among patients with R/R cHL, with a low rate of SAEs, according to results of a study presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Cancer Therapy Advisor
06/04/2021
ASCO 2021: Recommendations From Dr Noël Milipied for Lymphoma and CLL

Noël Milpied MD, PhD, highlights notable sessions being presented at the ASCO Annual Meeting in the lymphoma space.

06/01/2021
Adding Bortezomib to Front-Line Induction in Mantle Cell Lymphoma Did Not Extend Progression-Free Survival

According to results of the ECOG-ACRIN E1411 randomized phase 2 trial, the addition of bortezomib to bendamustine-rituximab induction therapy did not significantly improve PFS in patients with MCL.

Cancer Therapy Advisor
06/04/2021
Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma

Genentech today announced that new data on mosunetuzumab, glofitamab, and polatuzumab vedotin in NHL are being presented at the 2021 ASCO Annual Meeting.

06/04/2021

ASCO 2021: Updates in NSCLC

Radiotherapy and Surgery Produce Comparable Outcomes in Operable Stage IA Non-Small Cell Lung Cancer

Long-term results from the STARS trial indicate that SABR is not inferior to VATS with mediastinal lymph node dissection in patients with operable stage IA non-small cell lung cancer.

Cancer Therapy Advisor
06/07/2021
More Widespread Biomarker Testing for NSCLC in Oncology Practices and More Testing in Black Patients: An Urgent Priority

Even though next-generation sequencing is recommended for biomarker testing for patients with NSCLC, the uptake among community oncology practices is suboptimal, and the uptake is even lower among

The ASCO Post
06/08/2021
Atezolizumab Reduces Risk of Disease Progression and Death in Patients With PD-L1–Expressing Early-Stage NSCLC

Atezolizumab given after CT to patients with resected stage II to IIIA NSCLC significantly improves DFS compared with best supportive care alone in patients whose tumors expressed PD-L1.

The ASCO Post
06/10/2021
NSCLC: Immune-Related AEs May Predict Survival Outcomes

Experiencing an immune-related adverse event during checkpoint inhibitor treatment may predict outcomes in patients with non-small cell lung cancer, exploratory analyses of phase 3 trials suggest.<

Medscape
06/07/2021
PD-L1 Expression in Macrophage-Like Cells Linked to PFS After Immunotherapy in Non-Small Cell Lung Cancer

New research suggests the size of cancer-associated macrophage-like cells and the level of PD-L1 expression in these cells may predict treatment outcomes in patients with non-small cell lung cancer

Cancer Therapy Advisor
06/11/2021

ASCO 2021: Updates in Breast Cancer

Endocrine Therapy Proves Noninferior to Chemotherapy in HR+, HER2+ Metastatic Breast Cancer

Trastuzumab plus endocrine therapy proved safer than trastuzumab plus CT, with similar survival outcomes, in a phase 3 trial of patients with HR+, HER2+ metastatic breast cancer.

Cancer Therapy Advisor
06/16/2021
Use of Integrative Medicine by Patients With Breast Cancer

Nearly three-quarters of patients with breast cancer (73%) reported using at least one type of complementary medicine after cancer diagnosis, while surveyed oncologists believed that...

The ASCO Post
06/07/2021
Palbociclib Plus Fulvestrant Increases Long-Term Survival in Advanced Breast Cancer

A clinically meaningful long-term improvement in OS was seen with palbociclib plus fulvestrant in patients with HR+ and HER2- advanced breast cancer...

Cancer Therapy Advisor
06/06/2021
ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer

The first OS analysis of the WSG-ADAPT HR-/HER2+ study, which evaluates neoadjuvant therapy in patients with HR- HER2+ breast cancer, shows that treatment with pertuzumab and trastuzumab plus...

The ASCO Post
06/07/2021
OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer

One year of adjuvant therapy with the PARP inhibitor olaparib extended DFS in patients with high-risk, early-stage, HER2- breast cancer with BRCA1/2 germline mutations...

The ASCO Post
06/04/2021

ASCO 2021: Updates in Lung Cancer

No Survival Difference With Once-Daily vs Twice-Daily Radiotherapy in Small Cell Lung Cancer

Once-daily, high-dose thoracic radiotherapy does not significantly improve survival compared with lower-dose, twice-daily TRT for LSCLC, according to phase 3 trial results from the 2021 ASCO Annual

Cancer Therapy Advisor
06/09/2021
Urine Metabolites Could Predict End of Life in Lung Cancer

Lung cancer patients could soon have their risk of dying over the following 3 months accurately predicted by analyzing their urine samples, allowing them to better prepare for their end of life...<

Medscape
06/09/2021
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.

Cancer Therapy Advisor
06/14/2021
Atezolizumab Reduces Risk of Disease Progression and Death in Patients With PD-L1–Expressing Early-Stage NSCLC

Atezolizumab given after CT to patients with resected stage II to IIIA NSCLC significantly improves DFS compared with best supportive care alone in patients whose tumors expressed PD-L1.

The ASCO Post
06/10/2021
Less Pain, Fewer Complications With VATS vs Open Surgery in Early-Stage Lung Cancer

Video-assisted thoracoscopic surgery is associated with better physical function, less pain, and fewer complications, compared with open surgery, in patients with early-stage lung cancer.

Cancer Therapy Advisor
06/07/2021

ASCO 2021: Updates in Prostate Cancer

Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer

Lu-177–PSMA-617—an investigational radioligand therapy—significantly improves radiographic PFS and OS when added to standard of care compared with standard of care alone for men with mCRPC...

The ASCO Post
06/05/2021
Abiraterone Plus ADT and Docetaxel: A New SOC for Metastatic Castration-Sensitive Prostate Cancer?

Adding abiraterone to the current standard of care prolongs rPFS compared with SOC alone in patients with mCSPC, according to results of the phase 3 PEACE-1 trial presented at the 2021 ASCO Annual

Cancer Therapy Advisor
06/10/2021
Targeted Radiotherapy Offers New Treatment Option for Patients Previously Treated for Metastatic Castration-Resistant Prostate Cancer

The investigational therapy 177Lu-PSMA-617 significantly improved radiographic PFS and OS when added to standard of care treatment in patients with metastatic CRPC vs standard care alone, according

06/03/2021
Bone-Protecting Agents Reduce Fractures Associated With Treatment in Metastatic Castration-Resistant Prostate Cancer

Bone-protecting agents reduce the risk of bone fractures in patients with mCRPC who receive enzalutamide, with or without radium-223, according to results from a phase 3 trial.

Cancer Therapy Advisor
06/14/2021
FDA Approves Piflufolastat F-18 Injection, a PSMA PET Imaging Agent, for the Detection of Metastatic or Recurrent Prostate Cancer

The FDA approved piflufolastat F-18 injection, an F-18–labeled PSMA-targeted positron-emission tomography imaging agent, to identify suspected metastasis or recurrence of prostate cancer. 

The ASCO Post
06/10/2021

ASCO 2021: Updates in Solid Tumors

Targeting LAG-3 and PD-1 With Relatlimab and Nivolumab: A New Option Under Study in Advanced Melanoma

A novel immunotherapeutic combination—this one targeting the LAG-3 and PD-1 immune checkpoints—delays time to disease progression significantly more than nivolumab alone.

The ASCO Post
06/10/2021
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.

Cancer Therapy Advisor
06/14/2021
Does Vitamin D Supplementation Improve Prognosis for Patients With Breast Cancer?

A research team has found that sufficient vitamin D levels at the time of diagnosis may be associated with improved outcomes among people with breast cancer.

The ASCO Post
06/08/2021
Rising Incidence of Endometrial Cancer Linked to Obesity in Younger Women

An increase in endometrial cancer incidence among young adult women in the United States coincides with an increase in the prevalence of obesity in this population, according to researchers.

Cancer Therapy Advisor
06/21/2021
Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma

In a presentation of real-world data, Miron et al conclude that the choice of first-line platinum CT does not result in a significant difference in OS benefit among patients with advanced bladder..

The ASCO Post
06/08/2021
Spotlight

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834